Sygnature Discovery has expanded its DMPK capabilities with the acquisition of XenoGesis, an independent laboratory-based CRO specializing in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and interpretation.
This acquisition doubles the size of Sygnature’s DMPK department (established in 2015), broadening Sygnature’s discovery and development expertise, complementing its existing service-offering and adding new skills and capabilities.
"Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process, and we recognize the central role that DMPK plays in that journey,” Dr. Simon Hirst, CEO and Founder at Sygnature Discovery, said. "Sygnature is not growing for the sake of growing. We believe that truly integrated drug discovery is the best possible way forward in bringing novel efficacious drug candidates to man; that having teams working together across every discipline involved in a research project, sharing ideas and resolving challenges, will produce the sparks of innovation and high-quality science needed to enable success.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
The companies are both located at BioCity in Nottingham, UK, fitting well with Sygnature’s driving ethos of having co-located, multi-disciplinary teams of expert research scientists, working efficiently together, facilitating seamless drug discovery and creating innovative solutions for its partners
"Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations. From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers,” Dr. Richard Weaver, CEO and Founder at XenoGesis said. "Therefore, this step feels like a very natural one, and we are very excited about what we can accomplish together in helping accelerate our customers’ projects towards the clinic. My team and I are looking forward to joining forces with Sygnature."